Synapse - Long-term survival from a phase 1 doseescalation trial using convection-enhanced delivery (CED) of radioimmunotherapeutic (124)I-omburtamab for treatment of diffuse intrinsic pontine glioma (DIPG)

Long-term survival from a phase 1 doseescalation trial using convection-enhanced delivery (CED) of radioimmunotherapeutic (124)I-omburtamab for treatment of diffuse intrinsic pontine glioma (DIPG) Meeting Abstract

Authors:	Souweidane, M. M.; Kramer, K.; Pandit-Tasker, N.; Haque, S.; Zanzonico, P.; Carrasquillo, J.; Lyashchenko, S. K.; Thakur, S. B.; Khakoo, Y.; Dunkel, I. J.; Donzelli, M.; Lewis, J. S.; Cheung, N. K. V.; Larson, S. M.; Reiner, A. S.; Panageas, K. S.; Manino, N.; Nielsen, J. R.
Abstract Title:	Long-term survival from a phase 1 doseescalation trial using convection-enhanced delivery (CED) of radioimmunotherapeutic (124)I-omburtamab for treatment of diffuse intrinsic pontine glioma (DIPG)
Meeting Title:	20th International Symposium on Pediatric Neuro-Oncology (ISPNO 2022)
Journal Title:	Neuro-Oncology
Volume:	24
Issue:	Suppl. 1
Meeting Dates:	2022 Jun 12-15
Meeting Location:	Hamburg, Germany
ISSN:	1522-8517
Publisher:	Oxford University Press
Date Published:	2022-06-01
Start Page:	i30
End Page:	i31
Language:	English
ACCESSION:	WOS:000840122400112
PROVIDER:	wos
DOI:	10.1093/neuonc/noac079.110
Notes:	Meeting Abstract: DIPG-53 -- Source: Wos